Systematic reviews examining this intervention have reported that patients treated with GLP-1 receptor agonists after bariatric surgery achieved an average additional weight loss of 510% of total body weight over 612 months, though results vary considerably by individual, procedure type, and specific medication used
Check out their BeSafeRx website [archived link] for tips on safely purchasing prescription medications online
Check the trial phase
Comparatively, there were 210 adverse events reported on compounded semaglutide products
When patients are prescribed the medication, MOBO providers educate the patient how to self-inject the medication or how to have a friend inject the medication for you
Currently available GLP-1 receptor agonists in the United States include exenatide (Byetta, Bydureon BCise), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), semaglutide (Ozempic, Wegovy, Rybelsus), and tirzepatide (Mounjaro, Zepbound), though tirzepatide is technically a dual GIP/GLP-1 receptor agonist